Q-omics provides the consensus-scored STK11IP profile across patient tissues and cancer cell-line models. STK11IP expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, STK11IP is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, STK11IP RNA expression shows 19,559 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where STK11IP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STK11IP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STK11IP survival associations across molecular data types. STK11IP RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STK11IP RNA expression–survival associations across cancer types. High STK11IP expression shows unfavorable associations in ACC, LIHC, LGG and LUSC, but favorable associations in HNSC and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for STK11IP RNA expression.
This table summarizes STK11IP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for STK11IP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STK11IP shows lower tumor expression in KICH and higher tumor expression in LIHC, STAD, COAD, HNSC and BRCA. The LIHC box plot shows higher STK11IP RNA expression in tumor versus normal tissue (log2 FC = +1.401, t-test p < 0.001).
This table shows molecular features associated with STK11IP in patient tissues and cancer cell lines. In patient samples, STK11IP shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, STK11IP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
